These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 15496888)

  • 1. Antibiotics: a shot in the arm.
    Leeb M
    Nature; 2004 Oct; 431(7011):892-3. PubMed ID: 15496888
    [No Abstract]   [Full Text] [Related]  

  • 2. Antibiotics at the crossroads.
    Nathan C
    Nature; 2004 Oct; 431(7011):899-902. PubMed ID: 15496893
    [No Abstract]   [Full Text] [Related]  

  • 3. The antibacterial drugs market.
    Kresse H; Belsey MJ; Rovini H
    Nat Rev Drug Discov; 2007 Jan; 6(1):19-20. PubMed ID: 17269159
    [No Abstract]   [Full Text] [Related]  

  • 4. The new antibiotics.
    Breithaupt H
    Nat Biotechnol; 1999 Dec; 17(12):1165-9. PubMed ID: 10585711
    [No Abstract]   [Full Text] [Related]  

  • 5. A changing drug supply.
    Nature; 2007 Feb; 445(7127):460. PubMed ID: 17268432
    [No Abstract]   [Full Text] [Related]  

  • 6. Societal costs versus savings from wild-card patent extension legislation to spur critically needed antibiotic development.
    Spellberg B; Miller LG; Kuo MN; Bradley J; Scheld WM; Edwards JE
    Infection; 2007 Jun; 35(3):167-74. PubMed ID: 17565458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A testing approach based on tiny doses still awaits big results.
    Coombs A
    Nat Med; 2008 Aug; 14(8):796. PubMed ID: 18685584
    [No Abstract]   [Full Text] [Related]  

  • 8. Orphan drugs of the future?
    Service RF
    Science; 2004 Mar; 303(5665):1798. PubMed ID: 15031491
    [No Abstract]   [Full Text] [Related]  

  • 9. Drug companies snub antibiotics as pipeline threatens to run dry.
    Clarke T
    Nature; 2003 Sep; 425(6955):225. PubMed ID: 13679874
    [No Abstract]   [Full Text] [Related]  

  • 10. The antibiotic pipeline--challenges, costs, and values.
    Wenzel RP
    N Engl J Med; 2004 Aug; 351(6):523-6. PubMed ID: 15295041
    [No Abstract]   [Full Text] [Related]  

  • 11. Antibiotic development: a victim of market forces?
    Tillotson GS
    IDrugs; 2008 May; 11(5):340-6. PubMed ID: 18465675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fix the antibiotics pipeline.
    Cooper MA; Shlaes D
    Nature; 2011 Apr; 472(7341):32. PubMed ID: 21475175
    [No Abstract]   [Full Text] [Related]  

  • 13. Betting on biogenerics.
    Dove A
    Nat Biotechnol; 2001 Feb; 19(2):117-20. PubMed ID: 11175723
    [No Abstract]   [Full Text] [Related]  

  • 14. Trends in antimicrobial drug development: implications for the future.
    Spellberg B; Powers JH; Brass EP; Miller LG; Edwards JE
    Clin Infect Dis; 2004 May; 38(9):1279-86. PubMed ID: 15127341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The urgent need for new antibacterial agents.
    Wise R;
    J Antimicrob Chemother; 2011 Sep; 66(9):1939-40. PubMed ID: 21700627
    [No Abstract]   [Full Text] [Related]  

  • 16. A guiding hand for antibiotics.
    Jones D
    Nat Rev Drug Discov; 2011 Mar; 10(3):161-2. PubMed ID: 21358722
    [No Abstract]   [Full Text] [Related]  

  • 17. Billion-dollar market blossoms as botanicals take root.
    Glaser V
    Nat Biotechnol; 1999 Jan; 17(1):17-8. PubMed ID: 9920256
    [No Abstract]   [Full Text] [Related]  

  • 18. Antibacterial research and development in the 21(st) Century--an industry perspective of the challenges.
    Thomson CJ; Power E; Ruebsamen-Waigmann H; Labischinski H
    Curr Opin Microbiol; 2004 Oct; 7(5):445-50. PubMed ID: 15451498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The misuse of antibiotics.
    Levy SB; Star L; Kupferberg ED
    Med Ethics (Burlingt Mass); 2004; 11(1):5-8. PubMed ID: 15915579
    [No Abstract]   [Full Text] [Related]  

  • 20. Drug discovery.
    Kennedy D
    Science; 2004 Mar; 303(5665):1729. PubMed ID: 15031461
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.